- Home
- HCI vs BEAM Comparison
HCI vs BEAM Comparison
Compare HCI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- BEAM
- Stock Information
- Founded
- HCI 2006
- BEAM 2017
- Country
- HCI United States
- BEAM United States
- Employees
- HCI N/A
- BEAM N/A
- Industry
- HCI Property-Casualty Insurers
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCI Finance
- BEAM Health Care
- Exchange
- HCI Nasdaq
- BEAM Nasdaq
- Market Cap
- HCI 1.9B
- BEAM 1.6B
- IPO Year
- HCI N/A
- BEAM 2020
- Fundamental
- Price
- HCI $147.00
- BEAM $16.76
- Analyst Decision
- HCI Strong Buy
- BEAM Strong Buy
- Analyst Count
- HCI 4
- BEAM 11
- Target Price
- HCI $181.25
- BEAM $48.90
- AVG Volume (30 Days)
- HCI 131.5K
- BEAM 1.8M
- Earning Date
- HCI 08-07-2025
- BEAM 08-05-2025
- Dividend Yield
- HCI 1.10%
- BEAM N/A
- EPS Growth
- HCI 4.05
- BEAM N/A
- EPS
- HCI 10.46
- BEAM N/A
- Revenue
- HCI $759,870,000.00
- BEAM $63,578,000.00
- Revenue This Year
- HCI $19.25
- BEAM N/A
- Revenue Next Year
- HCI $4.08
- BEAM $8.82
- P/E Ratio
- HCI $13.92
- BEAM N/A
- Revenue Growth
- HCI 20.95
- BEAM N/A
- 52 Week Low
- HCI $83.65
- BEAM $13.53
- 52 Week High
- HCI $176.40
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- HCI 34.83
- BEAM 44.29
- Support Level
- HCI $153.88
- BEAM $16.18
- Resistance Level
- HCI $160.84
- BEAM $18.33
- Average True Range (ATR)
- HCI 5.27
- BEAM 1.10
- MACD
- HCI -2.39
- BEAM 0.00
- Stochastic Oscillator
- HCI 5.49
- BEAM 28.65
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.